Furthermore, Tacc3, as an important regulator of the cell cycle, has been shown to play a significant role in the development of various tumors, such as pancreatic cancer, bladder cancer, and the centrosome amplification process in highly invasive breast cancer cells.[42] Targeting Tacc3 has been demonstrated to induce immunogenic cell death in HER2‐positive breast cancer and enhance T‐DM1 response, making it a potential target for anti‐tumor drugs.[43] However, its role in DN and podocyte injury has not been reported and warrants further exploration. This evidence concerns the gene ERBB2 and urinary bladder carcinoma.